causal

Medicare Part B reimbursement rewards expensive chemo

A fourth driver is that the system pays doctors more for more expensive treatment: under Medicare Part B, oncologists who buy and administer chemotherapy in their own offices are reimbursed average sales price plus 6%, so a 6% margin on a $6,000 drug like Abraxane is far larger than 6% on a $600 drug like Taxol, creating a financial pull toward the costlier option.

causalpending

Speaker

Vincent Rajkumar

Evidence Quote

“Our system rewards doctors more for the more expensive treatment”

Source

Vincent Rajkumar on the High Price of Cancer Drugs— EconTalk
Created: 6/13/2026, 12:13:30 AM

Your notes

Loading notes...